Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group

Richard W. Tsang, Belinda A. Campbell, Jayant S. Goda, Chris R. Kelsey, Youlia M. Kirova, Rahul R. Parikh, Andrea K. Ng, Umberto Ricardi, Chang Ok Suh, Peter M. Mauch, Lena Specht, Joachim Yahalom

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Purpose: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. Methods and Materials: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. Results: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95%) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. Conclusions: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed.

Original languageEnglish
Pages (from-to)794-808
Number of pages15
JournalInternational Journal of Radiation Oncology Biology Physics
Volume101
Issue number4
DOIs
Publication statusPublished - 2018 Jul 15

Fingerprint

Radiation Oncology
Plasmacytoma
Multiple Myeloma
radiation therapy
Lymphoma
Radiotherapy
Guidelines
Plasma Cell Neoplasms
neoplasms
radiation
therapy
cells
Palliative Care
bones
Dose Fractionation
Bone and Bones
Therapeutics
recommendations
fractionation
planning

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Tsang, Richard W. ; Campbell, Belinda A. ; Goda, Jayant S. ; Kelsey, Chris R. ; Kirova, Youlia M. ; Parikh, Rahul R. ; Ng, Andrea K. ; Ricardi, Umberto ; Suh, Chang Ok ; Mauch, Peter M. ; Specht, Lena ; Yahalom, Joachim. / Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma : Guidelines From the International Lymphoma Radiation Oncology Group. In: International Journal of Radiation Oncology Biology Physics. 2018 ; Vol. 101, No. 4. pp. 794-808.
@article{c0956139d8764bbaa763f0c5ccc9fdbe,
title = "Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group",
abstract = "Purpose: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. Methods and Materials: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. Results: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95{\%}) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. Conclusions: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed.",
author = "Tsang, {Richard W.} and Campbell, {Belinda A.} and Goda, {Jayant S.} and Kelsey, {Chris R.} and Kirova, {Youlia M.} and Parikh, {Rahul R.} and Ng, {Andrea K.} and Umberto Ricardi and Suh, {Chang Ok} and Mauch, {Peter M.} and Lena Specht and Joachim Yahalom",
year = "2018",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2018.05.009",
language = "English",
volume = "101",
pages = "794--808",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

Tsang, RW, Campbell, BA, Goda, JS, Kelsey, CR, Kirova, YM, Parikh, RR, Ng, AK, Ricardi, U, Suh, CO, Mauch, PM, Specht, L & Yahalom, J 2018, 'Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group', International Journal of Radiation Oncology Biology Physics, vol. 101, no. 4, pp. 794-808. https://doi.org/10.1016/j.ijrobp.2018.05.009

Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma : Guidelines From the International Lymphoma Radiation Oncology Group. / Tsang, Richard W.; Campbell, Belinda A.; Goda, Jayant S.; Kelsey, Chris R.; Kirova, Youlia M.; Parikh, Rahul R.; Ng, Andrea K.; Ricardi, Umberto; Suh, Chang Ok; Mauch, Peter M.; Specht, Lena; Yahalom, Joachim.

In: International Journal of Radiation Oncology Biology Physics, Vol. 101, No. 4, 15.07.2018, p. 794-808.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma

T2 - Guidelines From the International Lymphoma Radiation Oncology Group

AU - Tsang, Richard W.

AU - Campbell, Belinda A.

AU - Goda, Jayant S.

AU - Kelsey, Chris R.

AU - Kirova, Youlia M.

AU - Parikh, Rahul R.

AU - Ng, Andrea K.

AU - Ricardi, Umberto

AU - Suh, Chang Ok

AU - Mauch, Peter M.

AU - Specht, Lena

AU - Yahalom, Joachim

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Purpose: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. Methods and Materials: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. Results: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95%) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. Conclusions: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed.

AB - Purpose: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. Methods and Materials: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. Results: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95%) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. Conclusions: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=85048743895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048743895&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.05.009

DO - 10.1016/j.ijrobp.2018.05.009

M3 - Review article

C2 - 29976492

AN - SCOPUS:85048743895

VL - 101

SP - 794

EP - 808

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -